Your session is about to expire
← Back to Search
Monoclonal Antibodies
A Study of SGN-CD228A in Advanced Solid Tumors
Phase 1
Waitlist Available
Research Sponsored by Seagen Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 3.5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial will test SGN-CD228A, a new drug, to see if it can safely treat patients with advanced solid tumors by stopping tumor growth or reducing their size.
Eligible Conditions
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Mesothelioma
- Pancreatic Cancer
- Skin Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to approximately 3.5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 3.5 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants with adverse events
Secondary study objectives
Duration of complete response
Duration of objective response (DOR)
Objective response rate (ORR)
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: SGN-CD228AExperimental Treatment1 Intervention
SGN-CD228A monotherapy
Find a Location
Who is running the clinical trial?
Seagen Inc.Lead Sponsor
210 Previous Clinical Trials
74,250 Total Patients Enrolled
Phillip Garfin, MD, PhDStudy DirectorSeagen Inc.
3 Previous Clinical Trials
175 Total Patients Enrolled
Anu Gupta, MDStudy DirectorSeagen Inc.
1 Previous Clinical Trials
58 Total Patients Enrolled